Brazilians will soon be able to choose the origin of CBD (Cannabidiol, a substance derived from Cannabis). This Thursday, 04, Promediol Brasil obtained the sanitary registration from Anvisa (Agency for Sanitary Surveillance) of the Extract from Cannabis Sativa, a more pompous name for the popular CBD (Cannabidiol, therapeutic substance derived from Cannabis, without psychoactive effect). The input comes from Switzerland, where the company’s headquarters are located.
In 2020, the first CBD registered by Anvisa was that of Prati-Donaduzzi from Paraná. The input is from the UK. There is also Canabidiol by Verdemed, approved a week ago, harvested and produced in Colombia.
Currently, among all the companies that were in the Anvisa queue, Promediol Brasil suffered a little more. In August, the partners were already celebrating the achievement, because the process appeared to be over. Just publishing the Official Diary of the Union. But the Brazilian partner at the laboratory, Adriana Schulz, had to wait to open the champagne.
The registration only came now, three months later. “Finally today we had the health authorization for our product”, said the entrepreneur on the phone today. Yes, she was elated.
The product is 100% natural. All Cannabis compounds were retained, such as terpenes and flavonoids, which boost the effect of CBD. Only THC (Tetrahydrocannabidiol, a substance with psychoactive effect) was removed, leaving less than 0.2% of it in the bottle. The indication is for the treatment of refractory epilepsy. But there are several studies that point to the effectiveness of the substance for the adjuvant treatment of anxiety.
Chad-98Weaver, a distinguished author at NewsBulletin247, excels in the craft of article writing. With a keen eye for detail and a penchant for storytelling, Chad delivers informative and engaging content that resonates with readers across various subjects. His contributions are a testament to his dedication and expertise in the field of journalism.
